This activity already occurred and is no longer available.
Breast Cancer Imaging and Treatment: State of the Art Part I
Breast Cancer Imaging and Treatment: State of the Art Part I

Breast Cancer Imaging and Treatment: State of the Art 2011 Part I

Release date: 07-15-11
Expiration date: 06-30-14


Authors

Larry Norton, MD, has nothing to disclose.
Christopher E. Comstock, MD, has nothing to disclose.

Target Audience
Physicians, pharmacists, and technologists

Objectives
At the completion of this activity, the participant will be able to:

1. Identify appropriate populations who may benefit from screening MRI
2. Describe benefits and risks associated with breast MRI
3. Explain potential future applications of novel techniques with breast MRI, including diffusion weighted imaging for screening
4. Review PEM technology, with comparison to WBPET or PET/CT
5. Discuss PEM as an alternative to breast MRI with local extent of disease prior to surgery and response to primary (neoadjuvant) chemotherapy
6. Describe the procedure for PEM-guided biopsy
7. Explain the risk of local recurrence after breast conserving surgery in women selected for breast conservation without MRI
8. Describe the potential for unnecessarily extensive surgery caused by identification of subclinical disease with MRI
9. Identify patients in which the pre-op use of MRI has been shown to improve clinical outcomes
10. Explain the implications of imaging, pathologic, and clinical studies for optimizing the use of accelerated partial-breast irradiation
11. Explain the implications of imaging, pathologic, and clinial studies to select alternative treatment approaches of completion axillary dissection, axillary and breast irradiation, and breast irradiation
12. Describe the current clinical needs for breast cancer staging and response to therapy
13. List current indications for FDG PET/CT for these tasks
14. Describe future directions for molecular imaging for breast cancer locoregional staging and response evaluation
15. Review data for adjuvant and neoadjuvant chemotherapy for breast cancer
16. Review NCCN guidelines for adjuvant and neoadjuvant chemotherapy for breast cancer
17. Discuss need for imaging to assess response of neoadjuvant chemotherapy and hormonal therapy for breast cancer
18. Discuss the basic principles and performance characteristics of planar and SPECT bone scans, FDG PET of the bone, NaF of the bone and how integrating imaging information from CT and MRI enhance diagnosis
19. Describe how fusion images should be interpreted as well as pitfalls to the different imaging methods
20. Examine possible scenarios to deploy advance bone imaging in breast cancer so that more accurate staging is performed
21. Identify standard of care for neoadjuvant chemotherapy
22. Explain outcomes for neoadjuvant chemotherapy
23. Report PCR rate in neoadjuvant therapy
24. Evaluate and compare functional MRI techniques for evaluating breast cancer
25. Apply quantitative MRI approaches to measure breast tumor response to neoadjuvant treatment
26. Critically assess the role of breast MRI for measuring neoadjuvant treatment response and its potential as a predictive biomarker
27. Interpret pathology reports from post-treatment surgeries
28. Interpret which variables are prognostic
29. Interpret pathologic-radiologic correlations

Continuing Education Credit Information

AMA-PRA (Physician)
The Society for Nuclear Medicine and Medical Imaging, Inc. (SNMMI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

SNMMI designates this enduring material for a maximum of 9.75 AMA PRA Category 1 CreditTM. Physicians should claim only credit commensurate with the extent of their participation in the activity. To receive CE credit, learners must achieve a score of 80% on the post-course assessment and complete the evaluation. Release date: 07-15-11 Expiration date: 06-30-14


   

   

ACPE (Pharmacists)
The Society for Nuclear Medicine and Molecular Imaging, Inc. (SNMMI) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity has been designated as knowledge-based CPE. The universal program number for this enduring material is 0210-0000-11-301-H04-P. Total available credit for pharmacists is 9.75 hours or 0.975 CEUs. Release Date: 07-15-11 Expiration Date: 06-30-14 To receive CE credit, learners must achieve a score of 80% on the post-course assessment and complete the evaluation.


VOICE (Technologists)

The SNMMI, through its Verification of Involvement in Continuing Education (VOICE) program, has approved this journal article for a maximum of 9.75 continuing education hours (CEHs). VOICE-approved credit is recognized by most licensure states and by the NMTCB and ARRT as Category A credit. In order to receive CE credit, you must first complete the activity content. When completed, take the post-test assessment. You must obtain a score of 80% to receive the CE credit. You will have no more than 3 attempts to successfully complete the post-test. Release Date: 07-15-11 Expiration Date: 06-30-14 California Scope: 9.75 Imaging(I)/Non-Imaging(NI) / Radiopharmacy(R) / Therapy(T).

Minimum system requirements

Supported Internet Browsers:
- Microsoft Internet Explorer (version 7 or higher)
- Google Chrome (latest version)
- Mozilla Firefox (latest version)
- Apple Safari (version 4 or higher)

Plug-in: Adobe Acrobat Reader (
http://get.adobe.com/reader/)

For questions please contact the
Education Department.
©2014 SNMMI. All rights reserved.

For more information on our privacy policy, please click the link below.




Type:     Internet Activity (Enduring Material)
57 Registered Users